[Retracted] Might Patients with Metastatic Gastrointestinal Stromal Tumors Benefit from Operative Management? A Population-Based Retrospective Study
Table 1
Characteristics of patients with metastatic and non-metastatic GISTs.
Characteristic
Number of patients (%)
value
Metastatic GIST ()
Non-metastatic GIST ()
Age at diagnosis, y
0.720
<40
91 (7.4)
356 (7.1)
≥40
1147 (92.6)
4688 (92.9)
Gender
<0.001
Male
717 (57.9)
2480 (49.2)
Female
521 (42.1)
2564 (50.8)
Race
0.036
White
871 (70.4)
3394 (67.3)
Black
216 (17.4)
891 (17.7)
Other
146 (11.8)
713 (14.1)
Unknown
5 (0.4)
46 (0.9)
Marital statusa
0.075
Married
706 (57.0)
2919 (57.9)
Unmarried
487 (39.3)
1874 (37.2)
Unknown
45 (3.6)
251 (5.0)
Tumor site
<0.001
Stomach
585 (47.3)
3101 (61.5)
Small intestine
394 (31.8)
1374 (27.2)
Other digestive organs
176 (14.2)
377 (7.5)
Non-digestive organs
83 (6.7)
192 (3.8)
Tumor size, cm
<0.001
<2.0
41 (3.3)
460 (9.1)
2.0-4.9
142 (11.5)
1482 (29.4)
5.0-9.9
364 (29.4)
1810 (35.9)
≥10
691 (55.8)
1292 (25.6)
Grade
<0.001
Poor differentiated or undifferentiated
221 (17.9)
470 (9.3)
Well or moderately differentiated
136 (11.0)
1477 (29.3)
Unknown
881 (71.2)
3097 (61.4)
Surgery
<0.001
Yes
756 (61.1)
4666 (92.5)
No
482 (38.9)
378 (7.5)
Chemotherapy
<0.001
Yes
884 (71.4)
1768 (35.1)
No or unknownb
354 (28.6)
3276 (64.9)
aMarital status included married (including common law), unmarried (including single, separated, divorced, widowed, or domestic partner), and unknown. bThis represents individuals in SEER database with chemotherapy data entered as “No or unknown” was given. It is not possible to separate the true “No” from “true unknown” in the data set. This variable was used because of its importance to survival, despite its limitations.
